You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Geographical mismatch

Showing 1 - 25 of 573
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Coronary Artery Disease Trial in Genk (3DCT-scan, Angiography guided PCI)

Recruiting
  • Coronary Artery Disease
  • 3DCT-scan
  • Angiography guided PCI
  • Genk, Limburg, Belgium
    Ziekenhuis Oost-Limburg
Jan 29, 2022

ARDS Trial (PEEP increase, PEEP decrease)

Not yet recruiting
  • ARDS
  • PEEP increase
  • PEEP decrease
  • (no location specified)
Oct 10, 2022

Patient-Centered Care Survey

Enrolling by invitation
  • Infertility
    • Houston, Texas
      Inception Fertility, LLC
    Sep 29, 2023

    MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer Trial (S095029, Pembrolizumab 200 mg)

    Not yet recruiting
    • MSI-H/dMMR Gastroesophageal-junction Cancer
    • MSI-H/dMMR Gastric Cancer
    • (no location specified)
    Oct 30, 2023

    Endometrial Tumors, Endometrial Cancer Trial in Seoul (Nivolumab)

    Not yet recruiting
    • Endometrial Neoplasms
    • Endometrial Cancer
    • Seoul, Korea, Republic of
      Severance Hospital, Yonsei University Health System
    Mar 21, 2023

    Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma Trial in

    Recruiting
    • Recurrent Endometrial Adenocarcinoma
    • +8 more
    • Ipilimumab
    • Nivolumab
    • Iowa City, Iowa
    • +9 more
    Jan 27, 2023

    Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair Trial in China (S1,

    Not yet recruiting
    • Adenocarcinoma of the Stomach
    • +2 more
    • Hangzhou, Zhejiang, China
    • +4 more
    May 23, 2023

    Diet and Nutrition on Growth and Development in Young Children

    Recruiting
    • Nutrition
    • +6 more
      • Swat, Khyber Pakhtunkhwa, Pakistan
        Dr. Muhammad Shahzad
      Aug 25, 2023

      DELTA DESCRIBE: THE FRENCH COLLABORATIVE PROJECT

      Recruiting
      • Hepatitis D
      • Patients co-infected HBV/HDV
      • Limoges, France
        Chu Limoges
      Jun 27, 2023

      Colonic Tumors Trial (Dostarlimab, CAPEOX, FOLFOX)

      Not yet recruiting
      • Colonic Neoplasms
      • Dostarlimab
      • +2 more
      • (no location specified)
      May 3, 2023

      V/Q Mismatch as Predictor of Pulmonary Postoperative

      Completed
      • Anesthesia
      • +2 more
      • Measure of ventilation/perfusion (V/Q) mismatch using Beacon ALPE (Automatic Lung Paramether Estimator)
      • Ferrara, Italy
        Azienda Ospedaliero Universitaria Sant'Anna
      Jul 8, 2022

      Ischemic Stroke, Acute Trial in Montpellier (Endovascular treatment (EVT) + Best medical treatment (BMT), Best medical treatment

      Not yet recruiting
      • Ischemic Stroke, Acute
      • Endovascular treatment (EVT) + Best medical treatment (BMT)
      • Best medical treatment (BMT)
      • Montpellier, France
        Department of Neurology/ Stroke Unit, Hôpital Gui de Chauliac
      Apr 14, 2023

      Refractory Metastatic Colorectal Cancer, pMMR, MSS Trial in United States (RP2, RP3, atezolizumab)

      Not yet recruiting
      • Refractory Metastatic Colorectal Cancer
      • +2 more
      • RP2
      • +3 more
      • Los Angeles, California
      • +5 more
      Feb 24, 2023

      Colon Cancer Trial (Pembrolizumab)

      Not yet recruiting
      • Colon Cancer
      • (no location specified)
      Dec 14, 2022

      Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

      Completed
      • Metastatic Colorectal Adenocarcinoma
      • regorafenib plus anti-PD-1 antibodies
      • Changsha, Hunan, China
        Hunan Cancer hospital
      Jul 4, 2023

      Peripartum Cardiomyopathy Trial (Molecular and genetic screening)

      Not yet recruiting
      • Peripartum Cardiomyopathy
      • Molecular and genetic screening
      • (no location specified)
      May 18, 2023

      Aortoiliac Occlusive Disease, Stent Complication, Vascular Device Occlusion Trial in Valladolid (Aortoiliac angioplasty and

      Completed
      • Aortoiliac Occlusive Disease
      • +3 more
      • Aortoiliac angioplasty and stenting
      • Valladolid, Spain
        Valladolid Univeristy Hospital
      Aug 21, 2023

      Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)

      Not yet recruiting
      • Metastatic Colorectal Cancer
      • HX008
      • Investigator's Choice Chemotherapy
      • Hefei, Anhui, China
      • +9 more
      Dec 8, 2022

      Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma Trial in Houston

      Active, not recruiting
      • Advanced Colorectal Carcinoma
      • +24 more
      • Houston, Texas
        M D Anderson Cancer Center
      Oct 20, 2022

      Colorectal Cancer Trial in China (Tislelizumab)

      Recruiting
      • Colorectal Cancer
      • Bengbu, Anhui, China
      • +7 more
      Sep 13, 2022

      Malaria Genetic Surveillance in Cambodia

      Completed
      • Parasitology
      • +2 more
        • (no location specified)
        May 17, 2022

        Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

        Not yet recruiting
        • Adenocarcinoma - GEJ
        • Gastric Adenocarcinoma
        • (no location specified)
        Sep 26, 2023

        Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

        Active, not recruiting
        • Colorectal Cancer
        • IBI310 (anti-CTLA-4 antibody)
        • Sintilimab(anti-PD-1 antibody)
        • Beijing, China
          Beijing cancer hospital
        Sep 15, 2022

        Tau PET/CT Imaging in Mismatch Prospective Cohort Study

        Recruiting
        • Alzheimer's Disease
        • Philadelphia, Pennsylvania
          University of Pennsylvania
        Jan 6, 2023

        Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)

        Not yet recruiting
        • Solid Tumor
        • +2 more
        • favezelimab/pembrolizumab
        • +2 more
        • (no location specified)
        Sep 7, 2023